The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) study

Trial Profile

The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) study

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Fenofibrate (Primary) ; Metformin
  • Indications Hypertriglyceridaemia; Insulin resistance; Metabolic syndrome
  • Focus Therapeutic Use
  • Acronyms FAMA
  • Most Recent Events

    • 15 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 06 Dec 2007 The expected completion date for this trial is now 1 Nov 2008.
    • 06 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top